Overview of Topelia

Topelia's business model focuses on the development of its patented Antiviral Triple Therapy (ATT), designated TPL101, which combines the approved drugs ivermectin and doxycycline with zinc. Initially targeting COVID-19 infection, TPL101 leverages the safety and efficacy of well-established medications, significantly reducing the development timeline and associated costs.

By utilising these proven components, Topelia is also minimising the risks typically involved in new drug development. After consulting with regulatory groups, the company will advance clinical development with two Phase 1 trials and a modestly sized Phase 3 trial.

If progress continues as planned Topelia aims to submit its application for TGA approval of TPL101 in 2025.